Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
FDA Breakthrough Device Designation means that the FDA has officially recognized a medical device as offering a significant advantage over existing alternatives for diagnosing or treating a serious condition. In May 2026, the TOBY Alzheimer’s urine test received this designation, signaling that federal regulators believe this simple diagnostic tool could meaningfully improve how doctors identify Alzheimer’s disease in patients showing early cognitive decline. Breakthrough status is not FDA approval—the device still needs to complete clinical review—but it’s an important milestone that can accelerate the path to availability and signals genuine regulatory confidence in the innovation.
This designation matters for people with cognitive concerns and their families because it means a potentially faster route to getting a urine-based test into clinical use instead of waiting for standard regulatory timelines. Rather than the typical 3 to 10-year journey many medical devices face, a Breakthrough-designated device can move through FDA review on an expedited track, potentially cutting years off the timeline to market. For someone worried about memory loss, the difference between waiting five years for a test versus two years represents a significant shift in when early detection becomes possible.
Table of Contents
- How Does FDA Breakthrough Device Designation Accelerate Device Approval?
- What Clinical Evidence Supports Urine-Based Alzheimer’s Diagnosis?
- Who Can Benefit From the TOBY Alzheimer’s Urine Test?
- What’s the Timeline From Breakthrough Designation to Clinical Availability?
- What Limitations Should You Know About Urine-Based Alzheimer’s Testing?
- How Do Urine-Based Tests Compare to Other Alzheimer’s Biomarkers?
- What Does FDA Breakthrough Status Mean for Future Alzheimer’s Diagnostics?
- Conclusion
How Does FDA Breakthrough Device Designation Accelerate Device Approval?
The FDA created the Breakthrough Devices Program in 2015 specifically to speed approval of innovations that could provide more effective diagnosis or treatment for life-threatening or irreversibly debilitating conditions. Alzheimer’s disease clearly qualifies—it’s irreversible, progressive, and affects more than 6 million Americans currently. When the FDA grants Breakthrough status, it’s pledging to prioritize that device’s review, reduce administrative delays, and allow for more interactive communication between the company and regulators during development. The practical effect is measurable. A standard FDA pre-submission meeting takes about 75 days to schedule; a Breakthrough device gets one scheduled in approximately 45 days. The FDA targets responding to an initial designation request within 60 calendar days, with any requests for additional information due within 30 days.
This compressed timeline matters because each month of delay is time when patients continue without access to a potentially useful diagnostic tool. For the TOBY urine test, expedited review could mean the difference between waiting five years versus two to three years for the test to reach clinical labs. However, expedited review doesn’t mean the clinical evidence standards are lowered. The test still must demonstrate safety and effectiveness through rigorous clinical trials. The FDA simply dedicates more resources to reviewing the submitted data faster rather than letting it sit in a queue. Some devices still fail or require substantial modifications even with Breakthrough status, so designation is encouraging but not a guarantee of success.
What Clinical Evidence Supports Urine-Based Alzheimer’s Diagnosis?
The science underlying urine-based Alzheimer’s tests is recent but increasingly validated. TOBY’s test analyzes volatile organic compounds (VOCs) found in urine using mass spectrometry and proprietary machine learning algorithms designed to detect patterns associated with Alzheimer’s pathology. These compounds are byproducts of the metabolic changes happening in the brains of people with Alzheimer’s disease, and they appear in detectable concentrations in urine long before symptoms become severe. Published research on comparable urine-based approaches shows promising performance metrics. Studies have reported sensitivity (the ability to correctly identify people with Alzheimer’s) ranging from 89.3% to 94%, and specificity (the ability to correctly identify people without Alzheimer’s) from 78% to 84.7%. To put this in perspective, a sensitivity of 89% means the test would correctly identify about 9 out of 10 people with Alzheimer’s.
Specificity of 85% means it would correctly rule out about 17 out of 20 people without the disease. These figures are comparable to some blood-based biomarker tests that have recently reached clinical use. The limitation worth understanding is that no single diagnostic test is perfect, and urine-based Alzheimer’s tests are still considered supportive tools rather than definitive diagnoses on their own. A positive TOBY test would typically be followed by additional evaluation—cognitive testing, imaging, or blood tests—to confirm the diagnosis. This reflects the reality that Alzheimer’s disease is complex, and diagnosis relies on clinical context, not a single number. Someone with a positive urine test and no cognitive symptoms would be approached differently than someone with a positive test and progressive memory loss.
Who Can Benefit From the TOBY Alzheimer’s Urine Test?
TOBY’s test is intended for adults ages 50 and older who are showing signs or symptoms of cognitive impairment and are undergoing evaluation for possible Alzheimer’s disease. This specifically targets people already in the diagnostic pathway—someone whose family noticed memory changes, or who scored concerning results on cognitive screening tests at their doctor’s office. It’s not a screening test for people without symptoms, but rather a tool to support diagnosis in someone already suspected of having cognitive decline. For a real-world example, consider an 68-year-old who has noticed difficulty remembering recent events and whose adult children expressed concern about changes they’ve observed. Their primary care doctor might perform a brief cognitive screening test (like the Montreal Cognitive Assessment), and if results suggest possible Alzheimer’s, ordering a TOBY urine test could be the next step.
The test would be non-invasive—simpler than a blood draw and faster than waiting weeks for an MRI appointment—providing diagnostic information that helps narrow whether cognitive decline is truly Alzheimer’s or something else, like depression, medication side effects, or normal aging. The practical advantage is accessibility. Not every community has neurologists or memory specialists readily available. A simple urine test could be performed in a primary care office, urgent care setting, or hospital lab, making diagnostic support available in settings where advanced neurological testing isn’t possible. However, this also means the test’s effectiveness depends partly on who orders it and how results are interpreted—a positive test ordered inappropriately or misunderstood by a provider who isn’t trained in neurology could lead to unnecessary worry or incorrect assumptions.
What’s the Timeline From Breakthrough Designation to Clinical Availability?
Breakthrough Device Designation typically shortens the path to market, but “expedited” is relative. Industry data suggests Breakthrough devices take approximately 2 to 5 years from designation to FDA authorization, with priority review potentially shortening timelines by 30 to 50 percent depending on device complexity and the quality of submitted clinical evidence. TOBY received its designation on May 26, 2026, which means if the company meets the fastest timelines and all clinical studies proceed without major setbacks, a urine test could potentially be available in clinical labs by 2028 or 2029. Compare this to the standard FDA pathway: a non-Breakthrough device diagnostic test could spend 2-3 years in pre-clinical development, 3-5 years in clinical trials, and another 1-2 years in FDA review—potentially 6-10 years total. The Breakthrough program collapses this timeline by allowing parallel development activities, expedited review of submitted data, and potentially smaller or more streamlined clinical trials if the evidence is compelling.
For context, some recent blood-based Alzheimer’s biomarker tests (like phosphorylated tau and amyloid blood tests) took roughly 5-7 years from initial research to FDA clearance. The tradeoff is that families and patients shouldn’t expect immediate access. Even with expedited review, clinical validation takes time, and rushing through insufficient evidence would be irresponsible. A 2 to 3-year wait from now (2028-2029) is still faster than would occur without Breakthrough status, but it’s not an immediate solution for someone currently worried about cognitive changes. In the interim, existing diagnostic tools—cognitive testing, imaging, blood biomarkers, specialist evaluation—remain the standard approaches.
What Limitations Should You Know About Urine-Based Alzheimer’s Testing?
Urine-based tests for Alzheimer’s are still relatively new compared to cognitive and imaging assessments that have been refined over decades. Although the TOBY test’s early research is promising, the data comes from relatively small studies published in peer-reviewed journals but not yet from the large-scale clinical trials that would be expected before FDA authorization. The performance metrics (89-94% sensitivity) are encouraging but based on research settings, not necessarily real-world practice where factors like dehydration, medication use, diet, and other health conditions might affect urine composition and test results. Another important limitation is that urine-based tests detect biomarker patterns associated with Alzheimer’s pathology, but biomarkers don’t always correlate perfectly with symptomatic disease. Some people can have Alzheimer’s-like pathology in their brain without significant cognitive symptoms, while others with clear cognitive decline may have mixed pathology (Alzheimer’s plus other brain changes like Lewy bodies or frontotemporal changes).
A positive TOBY test, even a highly accurate one, doesn’t replace the need for clinical evaluation including cognitive assessment, medical history, and sometimes imaging or specialist input. There’s also a practical warning: as urine tests become more widely available, there’s a risk they could be ordered too broadly or interpreted too simply. A urine test result reduced to “positive” or “negative” without clinical context could cause unnecessary alarm or false reassurance. A person with a positive urine test but no actual cognitive symptoms should not be diagnosed with Alzheimer’s disease, yet without proper education among primary care providers, that misinterpretation could occur. The test is a tool to support diagnosis in appropriate clinical contexts, not a standalone diagnostic certificate.
How Do Urine-Based Tests Compare to Other Alzheimer’s Biomarkers?
The diagnostic landscape for Alzheimer’s has expanded dramatically in recent years. Blood biomarker tests measuring phosphorylated tau (p-tau), phosphorylated tau-217 (p-tau217), and amyloid-beta have been FDA-cleared and are now in clinical use. These blood tests show excellent sensitivity and specificity—often 90% or higher—and have the advantage of detecting specific Alzheimer’s pathology proteins. Imaging tests like PET scans can visualize amyloid and tau in the brain directly, though they’re expensive and not always accessible.
Urine-based testing represents a different approach: instead of measuring specific proteins or imaging the brain, it detects patterns of volatile organic compounds that reflect the metabolic disturbances of Alzheimer’s disease. The advantage is simplicity and accessibility—urine collection is non-invasive and can happen in any setting without specialized equipment. The tradeoff is that urine testing is less specific to particular pathological proteins, so it might be less precise in distinguishing pure Alzheimer’s disease from other types of neurodegeneration. A positive urine test might indicate significant cognitive pathology, but whether that pathology is Alzheimer’s, mixed dementia, or something else might require follow-up blood biomarkers or imaging.
What Does FDA Breakthrough Status Mean for Future Alzheimer’s Diagnostics?
The FDA’s decision to grant Breakthrough status to TOBY’s urine test reflects growing regulatory recognition that early, accessible diagnosis of Alzheimer’s disease is critical. As more disease-modifying treatments reach clinical availability—therapies that slow cognitive decline if started early enough—diagnostic tools become more valuable. If people can be identified as having Alzheimer’s pathology before significant symptoms develop, those emerging treatments might have more impact. This creates a feedback loop where better diagnostics drive demand for earlier treatments, and available treatments drive demand for better diagnostics.
The Breakthrough designation is also a signal to other companies developing alternative diagnostic approaches. It tells the medical device industry that the FDA welcomes innovation in Alzheimer’s diagnosis and will prioritize review of genuinely promising tools. Over the next 5-10 years, expect to see multiple new diagnostic approaches—perhaps saliva-based tests, breath-based biomarkers, or other novel platforms—seeking Breakthrough or other expedited FDA pathways. The goal shared by regulators, researchers, and clinicians is to make early Alzheimer’s diagnosis as routine, accessible, and reliable as screening for other serious conditions like heart disease or cancer.
Conclusion
FDA Breakthrough Device Designation for the TOBY Alzheimer’s urine test represents recognition that a simple, non-invasive diagnostic tool could significantly improve how doctors identify Alzheimer’s disease in people with cognitive concerns. The designation doesn’t mean the test is immediately available—clinical trials and FDA authorization still lie ahead, likely requiring 2 to 3 more years—but it does mean regulators believe this approach has genuine merit and will prioritize its review accordingly. For families watching a loved one experience memory changes, this is encouraging news that faster, simpler diagnostic options are in the pipeline.
If you or a family member is currently facing cognitive concerns, don’t wait for urine-based tests to become available. Speak with your primary care doctor about cognitive screening, ask for referral to a neurologist or memory specialist if cognitive changes are real, and discuss whether blood biomarker testing or imaging might be appropriate now. The TOBY test and similar innovations will be valuable additions to diagnostic options, but they’ll work best as part of a comprehensive approach to cognitive assessment and care.
You Might Also Like
- What a Positive Alzheimer’s Blood Test Might Actually Mean
- Could a New Blood Test Change How Alzheimer’s Is Detected?
- Could Urine Tests Become the Next Alzheimer’s Diagnostic Tool?
Related reading
- how to Build a Dementia Risk Reduction Checklist
- what Practical Brain Health Planning Looks Like
- can Dementia Research Become More Patient-Centered
- why Families Need Studies That Reflect Daily Life
- how Caregiver Priorities Differ From Lab Outcomes
For more on this topic, see CDC — Alzheimer’s and Dementia.
